ATE353231T1 - Pharmazeutische zusammensetzungen - Google Patents

Pharmazeutische zusammensetzungen

Info

Publication number
ATE353231T1
ATE353231T1 AT03793261T AT03793261T ATE353231T1 AT E353231 T1 ATE353231 T1 AT E353231T1 AT 03793261 T AT03793261 T AT 03793261T AT 03793261 T AT03793261 T AT 03793261T AT E353231 T1 ATE353231 T1 AT E353231T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
asthma
preparing
processes
treatment
Prior art date
Application number
AT03793261T
Other languages
English (en)
Inventor
Stefan A Sharpe
Joel A Sequeira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE353231T1 publication Critical patent/ATE353231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/49826—Assembling or joining
    • Y10T29/49908—Joining by deforming

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT03793261T 2002-08-23 2003-08-21 Pharmazeutische zusammensetzungen ATE353231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40556302P 2002-08-23 2002-08-23

Publications (1)

Publication Number Publication Date
ATE353231T1 true ATE353231T1 (de) 2007-02-15

Family

ID=31946896

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793261T ATE353231T1 (de) 2002-08-23 2003-08-21 Pharmazeutische zusammensetzungen

Country Status (10)

Country Link
US (2) US20040086465A1 (de)
EP (1) EP1542753B1 (de)
JP (2) JP2005536538A (de)
AT (1) ATE353231T1 (de)
AU (1) AU2003259986A1 (de)
CA (1) CA2495689A1 (de)
DE (1) DE60311665T2 (de)
ES (2) ES2388537T3 (de)
MX (1) MXPA05002060A (de)
WO (1) WO2004018025A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
CA2495875C (en) * 2002-08-27 2010-06-22 Schering Corporation Process for producing metered dose inhaler formulations
CN1870976A (zh) * 2003-10-20 2006-11-29 先灵公司 药物组合物
DK1711164T3 (da) * 2004-01-21 2010-07-19 Schering Corp Fremgangsmåde til behandling af akut rhinosinusitis
CA2575932A1 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
US20070203104A1 (en) * 2006-02-09 2007-08-30 Chaudhry Saeed M Pharmaceutical Formulations
US8206687B2 (en) * 2006-10-26 2012-06-26 Next Breath, Llc Phospholipid-based inhalation system
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
AU2010253776B2 (en) 2009-05-29 2015-01-22 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
ATE539148T1 (de) * 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243061A (en) * 1991-06-10 1993-09-27 Schering Corp Aerosol containing a medicament and 1,1,1,2,3,3,3-heptafluoropropane
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
IL128714A (en) * 1996-08-29 2003-05-29 Schering Corp Chlorofluorocarbon-free mometasone furoate aerosol formulations
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2001064274A2 (en) * 2000-03-01 2001-09-07 Glaxo Group Limited Metered dose inhaler
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
CA2425035A1 (en) * 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
JP2005536538A (ja) * 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
CA2495875C (en) * 2002-08-27 2010-06-22 Schering Corporation Process for producing metered dose inhaler formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products

Also Published As

Publication number Publication date
WO2004018025A1 (en) 2004-03-04
JP2006312649A (ja) 2006-11-16
EP1542753B1 (de) 2007-02-07
DE60311665T2 (de) 2007-10-25
CA2495689A1 (en) 2004-03-04
EP1542753A1 (de) 2005-06-22
DE60311665D1 (de) 2007-03-22
AU2003259986A1 (en) 2004-03-11
US20040086465A1 (en) 2004-05-06
JP2005536538A (ja) 2005-12-02
MXPA05002060A (es) 2005-06-08
US20100095963A1 (en) 2010-04-22
ES2388537T3 (es) 2012-10-16
ES2281691T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
MXPA04001875A (es) Composiciones farmaceuticas para el tratamiento de asma.
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
SE0301700D0 (sv) Novel compounds
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
SE0302139D0 (sv) Novel compounds
ATE353231T1 (de) Pharmazeutische zusammensetzungen
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
ATE497967T1 (de) Interzelluläre kommunikation erleichternden verbindungen und deren medizinischen verwendungen
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
MXPA04005552A (es) Analogos de vitamina d.
SE0200657D0 (sv) Novel Formulation
AU2003281193A1 (en) Quinazoline derivatives for use in the treatment of cancer
WO2005030142A8 (en) Rifalazil formulations
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
SE0103210D0 (sv) New formulations and use thereof
SE0300830D0 (sv) New formulations and use thereof
ZA200605653B (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties